打破医院成果转化率8%“魔咒”，上海给体制机制动手术

Core Viewpoint - The article discusses the challenges and reforms in transforming the vast untapped intangible assets of public hospitals in China, particularly focusing on Shanghai's initiatives to enhance the conversion rate of medical research outcomes, which currently stands at a mere 8% compared to developed countries. Group 1: Challenges in Technology Transfer - China's medical technology conversion rate is below 8%, indicating a structural dilemma of "rich in research but poor in conversion" [2] - Public hospital patents are classified as state-owned assets, complicating the evaluation, pricing, and transfer processes, leading to inefficiencies and fears of asset loss [2][10] - The traditional process involves extensive bureaucratic hurdles, often taking over a year for a single patent transfer due to the need for multiple departmental approvals [2][3] Group 2: Shanghai's Reform Initiatives - Shanghai is implementing reforms to decentralize the rights to use, dispose of, and benefit from scientific achievements, aiming to break the conversion rate "curse" [1][2] - In 2022, Shanghai introduced operational guidelines to promote the conversion of scientific achievements in medical institutions, with 17 hospitals participating in pilot programs [2][12] - The introduction of "rights confirmation" and "due diligence exemption" is seen as key to overcoming existing barriers [2] Group 3: Successful Case Studies - Renji Hospital has seen a 575% increase in project numbers and a 210% increase in contract amounts since implementing a pilot program for managing scientific achievements [3] - Ruijin Hospital has developed a comprehensive service ecosystem for technology transfer, including a policy that allocates 80% of net conversion profits to research teams, addressing motivation issues among doctors [5][10] - Zhongshan Hospital has adopted a flexible pricing model that allows direct negotiations between inventors and companies, significantly reducing the time from rights confirmation to contract signing to just two months [8][9] Group 4: Future Prospects and Industry Support - The Shanghai government is actively supporting the biopharmaceutical industry with policies aimed at enhancing the entire innovation chain, from research to commercialization [12][13] - The establishment of the Guangci-Sinan National Translational Medicine Innovation Industrial Park is attracting numerous companies, with 283 companies and a registered capital of approximately 2.9 billion yuan by 2025 [7] - The Shanghai Children's Medical Center is set to launch a nationwide conversion project for a self-developed diagnostic kit, marking a significant step towards industrialization [10][11]